Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Мастодиния. Современные данные о причинах, течении, диагностике и подходах к коррекции
Мастодиния. Современные данные о причинах, течении, диагностике и подходах к коррекции
Лещенко О.Я. Мастодиния. Современные данные о причинах, течении, диагностике и подходах к коррекции. Гинекология. 2023;25(3):282–289. DOI: 10.26442/20795696.2023.3.202341
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Мастодиния является частым клиническим симптомом в общей врачебной и гинекологической практике. Задачи данного библиографического обзора: провести анализ научных сведений об эпидемиологии мастодинии/масталгии, о влиянии на качество жизни, противоречиях в определении этиологии, сформулировать диагностическую концепцию, классификацию, лечение, а также выяснить терапевтические эффекты Vitex Agnus-Castus. Проведен поиск научных публикаций в основных исследовательских базах данных, CochraneLibrary, PubMed, Science Direct, Google Scholar, ELibrary за последние 30 лет; использованы термины «масталгия/mastalgia», «мастодиния/mastodynia», «прутняк/Vitex Agnus-Castus», «боль в груди», «боль в молочных железах/chest pain, breast pain». Патофизиология мастодинии объясняется не одним механизмом, а разными причинами с независимыми путями формирования болезненных ощущений. Большинство исследований подчеркнули важность правильной классификации боли в молочных железах для точной диагностики и эффективной терапии, чтобы уменьшить частоту и выраженность эпизодов боли и улучшить качество жизни при минимизации побочных эффектов. Препараты на основе Vitex Agnus-Castus являются безопасными и эффективными в лечения мастодинии.
Ключевые слова: масталгия, мастодиния, Vitex Agnus-Castus, боль в груди, боль в молочных железах
Keywords: mastalgia, mastodynia, Vitex Agnus-Castus, chest pain, breast pain
Ключевые слова: масталгия, мастодиния, Vitex Agnus-Castus, боль в груди, боль в молочных железах
________________________________________________
Keywords: mastalgia, mastodynia, Vitex Agnus-Castus, chest pain, breast pain
Полный текст
Список литературы
1. Olawaiye A, Withiam-Leitch M, Danakas G, Kahn K. Mastalgia: a review of management. J Reprod Med. 2005;50(12):933-9.
2. Grullon S, Bechmann S. Mastodynia. In: StatPearls [Internet], Treasure Island (FL): StatPearls Publishing, 2022; 2023.
3. Stachs A, Stubert J, Reimer T, Hartmann S. Benign Breast Disease in Women. Dtsch Arztebl Int. 2019;116(33-34):565-74. DOI:10.3238/arztebl.2019.0565
4. Kataria K, Dhar A, Srivastava A, et al. A systematic review of current understanding and management of mastalgia. Indian J Surg. 2014;76(3):217-22. DOI:10.1007/s12262-013-0813-8
5. Кулагина Н.В., Одинцов В.А. Мастодиния: патогенез, диагностика, лечение. Акушерство и гинекология. 2022;6:33-9 [Kulagina NV, Odintsov VA. Mastodiniia: patogenez, diagnostika, lechenie. Akusherstvo i ginekologiia. 2022;6:33-9 (in Russian)]. DOI:10.18565/aig.2022-6.33-39
6. Kumar S, Rai R, Das V, et al. Visual analogue scale for assessing breast nodularity in non-discrete lumpy breasts: the Lucknow–Cardiff breast nodularity scale. Breast.
2010;19(3):238-42. DOI:10.1016/j.breast.2010.02.002
7. Scurr J, Hedger W, Morris P, Brown N. The prevalence, severity and impact of breast pain in the general population. Breast J. 2014;20(5):508‑13. DOI:10.1111/tbj.12305
8. Sutton GL, O’Malley VP. Treatment of cyclical mastalgia with low dose short term danazol. Br J Clin Pract. 1986;40(2):68-70.
9. Mansel RE, Dogliotti L. European multicenter trial of bromocriptine in cyclical mastalgia. Lancet. 1990;335(8683):190-3. DOI:10.1016/0140-6736(90)90278-d
10. Fentiman IS, Powles TJ. Tamoxifen and benign breast problems. Lancet. 1987;2(8567):1070-2. DOI:10.1016/s0140-6736(87)91491-7
11. Ader DN, South-Paul J, Adera T, Deuster PA. Cyclical mastalgia: prevalence and associated health behavioral factors. J Psychosom Obstet Gynaecol. 2001;22(2):71-6. DOI:10.3109/01674820109049956
12. Mansel RE, Webster DJT, Sweetland HM. Breast pain and nodularity. In: Benign disorders and disease of the breast. 3d ed. Philadelphia: Saunders, Elsevier, 2009.
13. Padden DL. Mastalgia: evaluation and management. Nurse Pract Forum. 2000;11(4):213-8.
14. Rungruang B, Kelley JL 3rd. Benign breast diseases: epidemiology, evaluation, and management. Clin Obstet Gynecol. 2011;54(1):110-24. DOI:10.1097/GRF.0b013e318208010e
15. Wisbey JR, Kumar S, Mansel RE, et al. Natural history of breast pain. Lancet. 1983;2(8351):672-4. DOI:10.1016/S0140-6736(83)92543-6
16. Goyal A. Breast pain. BMJ Clin Evid. 2011;2011:0812.
17. Malarkey WB, Schrooeder LL, Stevens VC, et al. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res.
1977;37(12):4655-9.
18. Sitruk-Ware R, Sterkers N, Mauvais-Jarvis P. Benign breast disease I: hormonal investigation. Obstet Gynecol. 1979;53(4):457-60.
19. Peters F, Pickcardt CR, Zimmermann G, Breckwoldt M. PRL, TSH and thyroid hormones in benign breast diseases. Klin Wochenschr. 1981;59(8):403-7. DOI:10.1007/BF01698519
20. Kumar S, Mansel RE, Scanlon MF, et al. Altered responses of prolactin, luteinizing hormone and follicle stimulating hormone secretion to thyrotrophin releasing hormone/gonadotropin releasing hormone stimulation in cyclical mastalgia. Br J Surg. 1984;71(11):870-3. DOI:10.1002/bjs.1800711123
21. Parlati E, Travaglini A, Liberale I, et al. Hormonal profile in benign breast disease: Endocrine status of cyclical mastalgia patients. J Endocrinol Invest. 1988;11(9):679-83. DOI:10.1007/BF03350214
22. Bonilla-Sepulveda OA, Giraldo-Santa DC. Mastodynia. CES Med. 2019;33(2):111-8. DOI:10.21615/cesmedicina.33.2.4
23. Ледина А.В., Прилепская В.Н. Масталгия: клиника, диагностика, лечение. Гинекология. 2011;13(5):66-76 [Ledina AV, Prilepskaya VN. Mastalgiya: klinika, diagnostika, lechenie. Gynecology. 2011;13(5):66-76 (in Russian)].
24. Лещенко О.Я. Гиперпролактинемия в период постменопаузы: версии и контраверсии. Терапевтический архив. 2021;93(10):1234-9 [Leshchenko OYa. Hyperprolactinemia in the postmenopause: versions and contraversions. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(10):1234‑9 (in Russian)]. DOI:10.26442/00403660.2021.10.201073
25. Bundred NJ. Breast pain. BMJ Clin Evid. 2007;2007:0812.
26. Лабыгина А.В., Сутурина Л.В., Лещенко О.Я., и др. Изменение пролактина на фоне приема современных оральных контрацептивов у девушек с функциональной гиперпролактинемией. Бюллетень ВСНЦ СО РАМН. 2006;1(47):79-81 [Labygina AV, Suturina LV, Leshenko OYa. Change of prolactin against a background of intake of oral contraceptives in girls with functional hyperprolactinemia. Biulleten' VSNTs SO RAMN. 2006;1(47):79-81 (in Russian)].
27. Boyle CA, Berkowitz GS, LiVolsi VA, et al. Caffeine consumption and fibrocystic breast disease: a case-control epidemiologic study. J Natl Cancer Inst. 1984;72(5):1015-9.
28. Levinson W, Dunn PM. Nonassociation of caffeine and fibrocystic breast disease. Arch Intern Med. 1986;146(9):1773-5.
29. Idiz C, Çakır C, Ulusoy Aİ, İdiz UO. The Role of Nutrition in Women with Benign Cyclic Mastalgia: A Case-Control Study. Eur J Breast Health. 2018;14(3):156-9. DOI:10.5152/ejbh.2018.3827
30. Preece PE, Mansel RE, Hughes LE. Mastalgia: psychoneurosis or organic disease? Br Med J. 1978;1(6104):29-30. DOI:10.1136/bmj.1.6104.29
31. Johnson KM, Bradley KA, Bush K, et al. Frequency of mastalgia among women veterans. Association with psychiatric conditions and unexplained pain syndromes. J Gen Intern Med. 2006;21Suppl. 3(Suppl. 3):S70-5. DOI:10.1111/j.1525-1497.2006.00378.x
32. Expert Panel on Breast Imaging: Jokich PM, Bailey L, D'Orsi C, et al. ACR Appropriateness Criteria® Breast Pain. J Am Coll Radiol. 2017;14(5S):S25‑33. DOI:10.1016/j.jacr.2017.01.028
33. Leung JW, Kornguth PJ, Gotway MB. Utility of targeted sonography in the evaluation of focal breast pain. J Ultrasound Med. 2002;21(5):521-6. DOI:10.7863/jum.2002.21.5.521
34. Tumyan L, Hoyt AC, Bassett LW. Negative predictive value of sonography and mammography in patients with focal breast pain. Breast J. 2005;11(5):333-7.
DOI:10.1111/j.1075-122X.2005.00018.x
35. Loving VA, DeMartini WB, Eby PR, et al. Targeted ultrasound in women younger than 30 years with focal breast signs or symptoms: outcomes analyses and management implications. AJR Am J Roentgenol. 2010;195(6):1472-7. DOI:10.2214/AJR.10.4396
36. Harper AP, Kelly-Fry E, Noe JS. Ultrasound breast imaging-the method of choice for examining the young patient. Ultrasound Med Biol. 1981;7(3):231-7.
DOI:10.1016/0301-5629(81)90033-8
37. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Heal. 1990;13(4):227-36. DOI:10.1002/nur.4770130405
38. Talimi-Schnabel J, Fink D. Mastodynie – wie soll man «Brustschmerz» abklären und behandeln? Praxis (Bern 1994). 2017;106(20):1101-6 (in German).
DOI:10.1024/1661-8157/a002795
39. Iddon J, Dixon JM. Mastalgia. BMJ. 2013;347:f3288. DOI:10.1136/bmj.f3288
40. Hadi MS. Sports brassiere: is it a solution for mastalgia? Breast J. 2000;6(6):407-9. DOI:10.1046/j.1524-4741.2000.20018.x
41. White J, Scurr J. Evaluation of professional bra fitting criteria for bra selection and fitting in the UK. Ergonomics. 2012;55(6):704-11.
DOI:10.1080/00140139.2011.647096
42. Jaiswal G, Thakur GS. An alternative yogic approach for cyclical mastalgia–A narrative review. J Family Med Prim Care. 2021;10(2):601-8. DOI:10.4103/jfmpc.jfmpc_1688_20
43. Yu C, Wang J, Shen B, et al. Effectiveness of acupuncture in the treatment of cyclic mastalgia: a study protocol for a randomized controlled trial. BMC Complement Med Ther. 2022;22(1):297. DOI:10.1186/s12906-022-03779-8
44. Yu GH, Zou LY, Liu JG. Combination of acupuncture with medication for treatment of hyperplasia of mammary glands in 46 cases. J Tradit Chin Med. 2010;30(3):232-4. DOI:10.1016/s0254-6272(10)60047-7
45. Wang Y. Acupuncture for treatment of hyperplasia of mammary gland and its effects on images and hemodynamics in the mammary gland. Zhongguo Zhen Jiu. 2005;25(9):619-21 (in Chinese).
46. Ernster VL, Goodson WH 3rd, Hunt TK, et al. Vitamin E and benign breast «disease»: double-blind, randomized clinical trial. Surgery. 1985;97(4):490-4.
47. Schürks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomized controlled trials. BMJ. 2010;341:c5702. DOI:10.1136/bmj.c5702
48. Колесникова Л.И., Сутурина Л.В., Гальченко Е.В., и др. Некоторые показатели антиоксидантной системы у женщин с дисгормональной мастопатией в динамике менструального цикла. Журнал акушерства и женских болезней. 2005;54(1):74-7 [Kolesnikova LI, Suturina LV, Gal'chenko EV, et al. Some parameters of antioxidant system in women with dyshormonal mastopathy in dynamics of menstrual cycle. Journal of obstetrics and women's diseases. 2005;54(1):74-7 (in Russian)]. DOI:10.17816/JOWD81580
49. Колесникова Л.И., Осипова Е.В., Гребенкина Л.А., и др. Окислительный стресс при диффузной мастопатии в различные фазы менструального цикла. Журнал акушерства и женских болезней. 2007;56(4):41‑5 [Kolesnikova LI, Osipova EV, Grеbenkina LA, et al. Oxidation stress in women with diffusion mastopathy in dinamics of menstrual cycle. Journal of obstetrics and women's diseases. 2007;56(4):41‑5 (in Russian)].
50. Goyal A, Mansel RE; Efamast Study Group. A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J. 2005;11(1):41-7. DOI:10.1111/j.1075-122X.2005.21492.x
51. Osouli Tabrizi S, Meedya S, Ghassab-Abdollahia N, et al. The effect of the herbal medicine on severity of cyclic mastalgia: a systematic review and meta-analysis. J Complement Integr Med. 2021;19(4):855-68. DOI:10.1515/jcim-2020-0531
52. Colak T, Ipek T, Kanik A, et al. Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment. J Am Coll Surg. 2003;196(4):525-30.
DOI:10.1016/S1072-7515(02)01893-8
53. Coney P, Washenik K, Langley RG, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception. 2001;63(6):297-302. DOI:10.1016/s0010-7824(01)00208-6
54. Uzan S, Denis C, Pomi V, Varin C. Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast disease. Eur J Obstet Gynecol Reprod Biol. 1992;43(3):219-27. DOI:10.1016/0028-2243(92)90177-z
55. Nappi C, Affinito P, Di Carlo C, et al. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease. J Endocrinol Invest. 1992;15(11):801-6. DOI:10.1007/BF03348808
56. Brkic M, Vujovic S, Ivanisevic MF, et al. The influence of progesterone gel therapy in the treatment of fibrocystic breast disease. Open J Obstet Gynecol. 2016;6(5):334-41. DOI:10.4236/ojog.2016.65042
57. Андреева Е.Н., Рожкова Н.И. Эффективность трансдермального геля, содержащего микронизированный прогестерон, в лечении фиброзно-кистозной мастопатии. Результаты российского исследования. Акушерство и гинекология. 2016;12:131-6 [Andreeva EN, Rozhkova NI. Efficacy of micronized progesterone-containing transdermal gel in the treatment of fibrocystic mastopathy: results of a russian study. Akusherstvo i ginekologiia. 2016;12:131-6 (in Russian)]. DOI:10.18565/aig.2016.12.131-6
58. Киселев В.И., Сметник В.П., Сутурина Л.В., и др. Индолкарбинол – метод мультитаргетной терапии при циклической мастодинии. Акушерство и гинекология.
2013;7:56-63 [Kiselev VI, Smetnik VP, Suturina LV, et al. Indole carbinol is a multitargeted therapy option for cyclic mastodynia. Akusherstvo i ginekologiia. 2013;7:56-63 (in Russian)].
59. Mansel RE, Goyal A, Preece P, et al. European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J Obstet Gynecol. 2004;191(6):1942-9. DOI:10.1016/j.ajog.2004.06.100
60. Srivastava A, Mansel RE, Arvind N, et al. Evidence-based management of mastalgia: a meta-analysis of randomized trials. Breast. 2007;16(5):503‑12. DOI:10.1016/j.breast.2007.03.003
61. Zeqiri A, Dermaku-Sopjani M, Sopjani M. The mechanisms underlying the role of Vitex agnus-castus in mastalgia. Bratisl Lek Listy. 2022;123(12):913-8. DOI:10.4149/BLL_2022_147
62. Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus)-pharmacology and clinical indications. Phytomedicine. 2003;10(4):348‑57. DOI:10.1078/094471103322004866
63. Carmichael AR. Can Vitex Agnus Castus be used for the treatment of mastalgia? What is the current evidence? Evid Based Complement Alternat Med. 2008;5(3):247-50. DOI:10.1093/ecam/nem074
64. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322(7279):134-7. DOI:10.1136/bmj.322.7279.134
65. Halaska M, Beles P, Gorkow C, Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast. 1999;8(4):175-81. DOI:10.1054/brst.1999.0039
66. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2003;18(3):191-5. DOI:10.1002/hup.470
67. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med. 2000;9(3):315-20. DOI:10.1089/152460900318515
68. Berger D, Schaffner W, Schrader E, et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet. 2000;264(3):150-3. DOI:10.1007/s004040000123
69. Ooi SL, Watts S, McClean R, Pak SC. Vitex Agnus-Castus for the Treatment of Cyclic Mastalgia: A Systematic Review and Meta-Analysis. J Womens Health (Larchmt). 2020;29(2):262-78. DOI:10.1089/jwh.2019.7770
2. Grullon S, Bechmann S. Mastodynia. In: StatPearls [Internet], Treasure Island (FL): StatPearls Publishing, 2022; 2023.
3. Stachs A, Stubert J, Reimer T, Hartmann S. Benign Breast Disease in Women. Dtsch Arztebl Int. 2019;116(33-34):565-74. DOI:10.3238/arztebl.2019.0565
4. Kataria K, Dhar A, Srivastava A, et al. A systematic review of current understanding and management of mastalgia. Indian J Surg. 2014;76(3):217-22. DOI:10.1007/s12262-013-0813-8
5. Kulagina NV, Odintsov VA. Mastodiniia: patogenez, diagnostika, lechenie. Akusherstvo i ginekologiia. 2022;6:33-9 (in Russian). DOI:10.18565/aig.2022-6.33-39
6. Kumar S, Rai R, Das V, et al. Visual analogue scale for assessing breast nodularity in non-discrete lumpy breasts: the Lucknow–Cardiff breast nodularity scale. Breast.
2010;19(3):238-42. DOI:10.1016/j.breast.2010.02.002
7. Scurr J, Hedger W, Morris P, Brown N. The prevalence, severity and impact of breast pain in the general population. Breast J. 2014;20(5):508‑13. DOI:10.1111/tbj.12305
8. Sutton GL, O’Malley VP. Treatment of cyclical mastalgia with low dose short term danazol. Br J Clin Pract. 1986;40(2):68-70.
9. Mansel RE, Dogliotti L. European multicenter trial of bromocriptine in cyclical mastalgia. Lancet. 1990;335(8683):190-3. DOI:10.1016/0140-6736(90)90278-d
10. Fentiman IS, Powles TJ. Tamoxifen and benign breast problems. Lancet. 1987;2(8567):1070-2. DOI:10.1016/s0140-6736(87)91491-7
11. Ader DN, South-Paul J, Adera T, Deuster PA. Cyclical mastalgia: prevalence and associated health behavioral factors. J Psychosom Obstet Gynaecol. 2001;22(2):71-6. DOI:10.3109/01674820109049956
12. Mansel RE, Webster DJT, Sweetland HM. Breast pain and nodularity. In: Benign disorders and disease of the breast. 3d ed. Philadelphia: Saunders, Elsevier, 2009.
13. Padden DL. Mastalgia: evaluation and management. Nurse Pract Forum. 2000;11(4):213-8.
14. Rungruang B, Kelley JL 3rd. Benign breast diseases: epidemiology, evaluation, and management. Clin Obstet Gynecol. 2011;54(1):110-24. DOI:10.1097/GRF.0b013e318208010e
15. Wisbey JR, Kumar S, Mansel RE, et al. Natural history of breast pain. Lancet. 1983;2(8351):672-4. DOI:10.1016/S0140-6736(83)92543-6
16. Goyal A. Breast pain. BMJ Clin Evid. 2011;2011:0812.
17. Malarkey WB, Schrooeder LL, Stevens VC, et al. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res.
1977;37(12):4655-9.
18. Sitruk-Ware R, Sterkers N, Mauvais-Jarvis P. Benign breast disease I: hormonal investigation. Obstet Gynecol. 1979;53(4):457-60.
19. Peters F, Pickcardt CR, Zimmermann G, Breckwoldt M. PRL, TSH and thyroid hormones in benign breast diseases. Klin Wochenschr. 1981;59(8):403-7. DOI:10.1007/BF01698519
20. Kumar S, Mansel RE, Scanlon MF, et al. Altered responses of prolactin, luteinizing hormone and follicle stimulating hormone secretion to thyrotrophin releasing hormone/gonadotropin releasing hormone stimulation in cyclical mastalgia. Br J Surg. 1984;71(11):870-3. DOI:10.1002/bjs.1800711123
21. Parlati E, Travaglini A, Liberale I, et al. Hormonal profile in benign breast disease: Endocrine status of cyclical mastalgia patients. J Endocrinol Invest. 1988;11(9):679-83. DOI:10.1007/BF03350214
22. Bonilla-Sepulveda OA, Giraldo-Santa DC. Mastodynia. CES Med. 2019;33(2):111-8. DOI:10.21615/cesmedicina.33.2.4
23. Ledina AV, Prilepskaya VN. Mastalgiya: klinika, diagnostika, lechenie. Gynecology. 2011;13(5):66-76 (in Russian).
24. Leshchenko OYa. Hyperprolactinemia in the postmenopause: versions and contraversions. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(10):1234‑9 (in Russian). DOI:10.26442/00403660.2021.10.201073
25. Bundred NJ. Breast pain. BMJ Clin Evid. 2007;2007:0812.
26. Labygina AV, Suturina LV, Leshenko OYa. Change of prolactin against a background of intake of oral contraceptives in girls with functional hyperprolactinemia. Biulleten' VSNTs SO RAMN. 2006;1(47):79-81 (in Russian).
27. Boyle CA, Berkowitz GS, LiVolsi VA, et al. Caffeine consumption and fibrocystic breast disease: a case-control epidemiologic study. J Natl Cancer Inst. 1984;72(5):1015-9.
28. Levinson W, Dunn PM. Nonassociation of caffeine and fibrocystic breast disease. Arch Intern Med. 1986;146(9):1773-5.
29. Idiz C, Çakır C, Ulusoy Aİ, İdiz UO. The Role of Nutrition in Women with Benign Cyclic Mastalgia: A Case-Control Study. Eur J Breast Health. 2018;14(3):156-9. DOI:10.5152/ejbh.2018.3827
30. Preece PE, Mansel RE, Hughes LE. Mastalgia: psychoneurosis or organic disease? Br Med J. 1978;1(6104):29-30. DOI:10.1136/bmj.1.6104.29
31. Johnson KM, Bradley KA, Bush K, et al. Frequency of mastalgia among women veterans. Association with psychiatric conditions and unexplained pain syndromes. J Gen Intern Med. 2006;21Suppl. 3(Suppl. 3):S70-5. DOI:10.1111/j.1525-1497.2006.00378.x
32. Expert Panel on Breast Imaging: Jokich PM, Bailey L, D'Orsi C, et al. ACR Appropriateness Criteria® Breast Pain. J Am Coll Radiol. 2017;14(5S):S25‑33. DOI:10.1016/j.jacr.2017.01.028
33. Leung JW, Kornguth PJ, Gotway MB. Utility of targeted sonography in the evaluation of focal breast pain. J Ultrasound Med. 2002;21(5):521-6. DOI:10.7863/jum.2002.21.5.521
34. Tumyan L, Hoyt AC, Bassett LW. Negative predictive value of sonography and mammography in patients with focal breast pain. Breast J. 2005;11(5):333-7.
DOI:10.1111/j.1075-122X.2005.00018.x
35. Loving VA, DeMartini WB, Eby PR, et al. Targeted ultrasound in women younger than 30 years with focal breast signs or symptoms: outcomes analyses and management implications. AJR Am J Roentgenol. 2010;195(6):1472-7. DOI:10.2214/AJR.10.4396
36. Harper AP, Kelly-Fry E, Noe JS. Ultrasound breast imaging-the method of choice for examining the young patient. Ultrasound Med Biol. 1981;7(3):231-7.
DOI:10.1016/0301-5629(81)90033-8
37. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Heal. 1990;13(4):227-36. DOI:10.1002/nur.4770130405
38. Talimi-Schnabel J, Fink D. Mastodynie – wie soll man «Brustschmerz» abklären und behandeln? Praxis (Bern 1994). 2017;106(20):1101-6 (in German).
DOI:10.1024/1661-8157/a002795
39. Iddon J, Dixon JM. Mastalgia. BMJ. 2013;347:f3288. DOI:10.1136/bmj.f3288
40. Hadi MS. Sports brassiere: is it a solution for mastalgia? Breast J. 2000;6(6):407-9. DOI:10.1046/j.1524-4741.2000.20018.x
41. White J, Scurr J. Evaluation of professional bra fitting criteria for bra selection and fitting in the UK. Ergonomics. 2012;55(6):704-11.
DOI:10.1080/00140139.2011.647096
42. Jaiswal G, Thakur GS. An alternative yogic approach for cyclical mastalgia–A narrative review. J Family Med Prim Care. 2021;10(2):601-8. DOI:10.4103/jfmpc.jfmpc_1688_20
43. Yu C, Wang J, Shen B, et al. Effectiveness of acupuncture in the treatment of cyclic mastalgia: a study protocol for a randomized controlled trial. BMC Complement Med Ther. 2022;22(1):297. DOI:10.1186/s12906-022-03779-8
44. Yu GH, Zou LY, Liu JG. Combination of acupuncture with medication for treatment of hyperplasia of mammary glands in 46 cases. J Tradit Chin Med. 2010;30(3):232-4. DOI:10.1016/s0254-6272(10)60047-7
45. Wang Y. Acupuncture for treatment of hyperplasia of mammary gland and its effects on images and hemodynamics in the mammary gland. Zhongguo Zhen Jiu. 2005;25(9):619-21 (in Chinese).
46. Ernster VL, Goodson WH 3rd, Hunt TK, et al. Vitamin E and benign breast «disease»: double-blind, randomized clinical trial. Surgery. 1985;97(4):490-4.
47. Schürks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomized controlled trials. BMJ. 2010;341:c5702. DOI:10.1136/bmj.c5702
48. Kolesnikova LI, Suturina LV, Gal'chenko EV, et al. Some parameters of antioxidant system in women with dyshormonal mastopathy in dynamics of menstrual cycle. Journal of obstetrics and women's diseases. 2005;54(1):74-7 (in Russian). DOI:10.17816/JOWD81580
49. Kolesnikova LI, Osipova EV, Grеbenkina LA, et al. Oxidation stress in women with diffusion mastopathy in dinamics of menstrual cycle. Journal of obstetrics and women's diseases. 2007;56(4):41‑5 (in Russian).
50. Goyal A, Mansel RE; Efamast Study Group. A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J. 2005;11(1):41-7. DOI:10.1111/j.1075-122X.2005.21492.x
51. Osouli Tabrizi S, Meedya S, Ghassab-Abdollahia N, et al. The effect of the herbal medicine on severity of cyclic mastalgia: a systematic review and meta-analysis. J Complement Integr Med. 2021;19(4):855-68. DOI:10.1515/jcim-2020-0531
52. Colak T, Ipek T, Kanik A, et al. Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment. J Am Coll Surg. 2003;196(4):525-30.
DOI:10.1016/S1072-7515(02)01893-8
53. Coney P, Washenik K, Langley RG, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception. 2001;63(6):297-302. DOI:10.1016/s0010-7824(01)00208-6
54. Uzan S, Denis C, Pomi V, Varin C. Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast disease. Eur J Obstet Gynecol Reprod Biol. 1992;43(3):219-27. DOI:10.1016/0028-2243(92)90177-z
55. Nappi C, Affinito P, Di Carlo C, et al. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease. J Endocrinol Invest. 1992;15(11):801-6. DOI:10.1007/BF03348808
56. Brkic M, Vujovic S, Ivanisevic MF, et al. The influence of progesterone gel therapy in the treatment of fibrocystic breast disease. Open J Obstet Gynecol. 2016;6(5):334-41. DOI:10.4236/ojog.2016.65042
57. Andreeva EN, Rozhkova NI. Efficacy of micronized progesterone-containing transdermal gel in the treatment of fibrocystic mastopathy: results of a russian study. Akusherstvo i ginekologiia. 2016;12:131-6 (in Russian). DOI:10.18565/aig.2016.12.131-6
58. Kiselev VI, Smetnik VP, Suturina LV, et al. Indole carbinol is a multitargeted therapy option for cyclic mastodynia. Akusherstvo i ginekologiia. 2013;7:56-63 (in Russian).
59. Mansel RE, Goyal A, Preece P, et al. European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J Obstet Gynecol. 2004;191(6):1942-9. DOI:10.1016/j.ajog.2004.06.100
60. Srivastava A, Mansel RE, Arvind N, et al. Evidence-based management of mastalgia: a meta-analysis of randomized trials. Breast. 2007;16(5):503‑12. DOI:10.1016/j.breast.2007.03.003
61. Zeqiri A, Dermaku-Sopjani M, Sopjani M. The mechanisms underlying the role of Vitex agnus-castus in mastalgia. Bratisl Lek Listy. 2022;123(12):913-8. DOI:10.4149/BLL_2022_147
62. Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus)-pharmacology and clinical indications. Phytomedicine. 2003;10(4):348‑57. DOI:10.1078/094471103322004866
63. Carmichael AR. Can Vitex Agnus Castus be used for the treatment of mastalgia? What is the current evidence? Evid Based Complement Alternat Med. 2008;5(3):247-50. DOI:10.1093/ecam/nem074
64. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322(7279):134-7. DOI:10.1136/bmj.322.7279.134
65. Halaska M, Beles P, Gorkow C, Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast. 1999;8(4):175-81. DOI:10.1054/brst.1999.0039
66. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2003;18(3):191-5. DOI:10.1002/hup.470
67. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med. 2000;9(3):315-20. DOI:10.1089/152460900318515
68. Berger D, Schaffner W, Schrader E, et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet. 2000;264(3):150-3. DOI:10.1007/s004040000123
69. Ooi SL, Watts S, McClean R, Pak SC. Vitex Agnus-Castus for the Treatment of Cyclic Mastalgia: A Systematic Review and Meta-Analysis. J Womens Health (Larchmt). 2020;29(2):262-78. DOI:10.1089/jwh.2019.7770
2. Grullon S, Bechmann S. Mastodynia. In: StatPearls [Internet], Treasure Island (FL): StatPearls Publishing, 2022; 2023.
3. Stachs A, Stubert J, Reimer T, Hartmann S. Benign Breast Disease in Women. Dtsch Arztebl Int. 2019;116(33-34):565-74. DOI:10.3238/arztebl.2019.0565
4. Kataria K, Dhar A, Srivastava A, et al. A systematic review of current understanding and management of mastalgia. Indian J Surg. 2014;76(3):217-22. DOI:10.1007/s12262-013-0813-8
5. Кулагина Н.В., Одинцов В.А. Мастодиния: патогенез, диагностика, лечение. Акушерство и гинекология. 2022;6:33-9 [Kulagina NV, Odintsov VA. Mastodiniia: patogenez, diagnostika, lechenie. Akusherstvo i ginekologiia. 2022;6:33-9 (in Russian)]. DOI:10.18565/aig.2022-6.33-39
6. Kumar S, Rai R, Das V, et al. Visual analogue scale for assessing breast nodularity in non-discrete lumpy breasts: the Lucknow–Cardiff breast nodularity scale. Breast.
2010;19(3):238-42. DOI:10.1016/j.breast.2010.02.002
7. Scurr J, Hedger W, Morris P, Brown N. The prevalence, severity and impact of breast pain in the general population. Breast J. 2014;20(5):508‑13. DOI:10.1111/tbj.12305
8. Sutton GL, O’Malley VP. Treatment of cyclical mastalgia with low dose short term danazol. Br J Clin Pract. 1986;40(2):68-70.
9. Mansel RE, Dogliotti L. European multicenter trial of bromocriptine in cyclical mastalgia. Lancet. 1990;335(8683):190-3. DOI:10.1016/0140-6736(90)90278-d
10. Fentiman IS, Powles TJ. Tamoxifen and benign breast problems. Lancet. 1987;2(8567):1070-2. DOI:10.1016/s0140-6736(87)91491-7
11. Ader DN, South-Paul J, Adera T, Deuster PA. Cyclical mastalgia: prevalence and associated health behavioral factors. J Psychosom Obstet Gynaecol. 2001;22(2):71-6. DOI:10.3109/01674820109049956
12. Mansel RE, Webster DJT, Sweetland HM. Breast pain and nodularity. In: Benign disorders and disease of the breast. 3d ed. Philadelphia: Saunders, Elsevier, 2009.
13. Padden DL. Mastalgia: evaluation and management. Nurse Pract Forum. 2000;11(4):213-8.
14. Rungruang B, Kelley JL 3rd. Benign breast diseases: epidemiology, evaluation, and management. Clin Obstet Gynecol. 2011;54(1):110-24. DOI:10.1097/GRF.0b013e318208010e
15. Wisbey JR, Kumar S, Mansel RE, et al. Natural history of breast pain. Lancet. 1983;2(8351):672-4. DOI:10.1016/S0140-6736(83)92543-6
16. Goyal A. Breast pain. BMJ Clin Evid. 2011;2011:0812.
17. Malarkey WB, Schrooeder LL, Stevens VC, et al. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res.
1977;37(12):4655-9.
18. Sitruk-Ware R, Sterkers N, Mauvais-Jarvis P. Benign breast disease I: hormonal investigation. Obstet Gynecol. 1979;53(4):457-60.
19. Peters F, Pickcardt CR, Zimmermann G, Breckwoldt M. PRL, TSH and thyroid hormones in benign breast diseases. Klin Wochenschr. 1981;59(8):403-7. DOI:10.1007/BF01698519
20. Kumar S, Mansel RE, Scanlon MF, et al. Altered responses of prolactin, luteinizing hormone and follicle stimulating hormone secretion to thyrotrophin releasing hormone/gonadotropin releasing hormone stimulation in cyclical mastalgia. Br J Surg. 1984;71(11):870-3. DOI:10.1002/bjs.1800711123
21. Parlati E, Travaglini A, Liberale I, et al. Hormonal profile in benign breast disease: Endocrine status of cyclical mastalgia patients. J Endocrinol Invest. 1988;11(9):679-83. DOI:10.1007/BF03350214
22. Bonilla-Sepulveda OA, Giraldo-Santa DC. Mastodynia. CES Med. 2019;33(2):111-8. DOI:10.21615/cesmedicina.33.2.4
23. Ледина А.В., Прилепская В.Н. Масталгия: клиника, диагностика, лечение. Гинекология. 2011;13(5):66-76 [Ledina AV, Prilepskaya VN. Mastalgiya: klinika, diagnostika, lechenie. Gynecology. 2011;13(5):66-76 (in Russian)].
24. Лещенко О.Я. Гиперпролактинемия в период постменопаузы: версии и контраверсии. Терапевтический архив. 2021;93(10):1234-9 [Leshchenko OYa. Hyperprolactinemia in the postmenopause: versions and contraversions. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(10):1234‑9 (in Russian)]. DOI:10.26442/00403660.2021.10.201073
25. Bundred NJ. Breast pain. BMJ Clin Evid. 2007;2007:0812.
26. Лабыгина А.В., Сутурина Л.В., Лещенко О.Я., и др. Изменение пролактина на фоне приема современных оральных контрацептивов у девушек с функциональной гиперпролактинемией. Бюллетень ВСНЦ СО РАМН. 2006;1(47):79-81 [Labygina AV, Suturina LV, Leshenko OYa. Change of prolactin against a background of intake of oral contraceptives in girls with functional hyperprolactinemia. Biulleten' VSNTs SO RAMN. 2006;1(47):79-81 (in Russian)].
27. Boyle CA, Berkowitz GS, LiVolsi VA, et al. Caffeine consumption and fibrocystic breast disease: a case-control epidemiologic study. J Natl Cancer Inst. 1984;72(5):1015-9.
28. Levinson W, Dunn PM. Nonassociation of caffeine and fibrocystic breast disease. Arch Intern Med. 1986;146(9):1773-5.
29. Idiz C, Çakır C, Ulusoy Aİ, İdiz UO. The Role of Nutrition in Women with Benign Cyclic Mastalgia: A Case-Control Study. Eur J Breast Health. 2018;14(3):156-9. DOI:10.5152/ejbh.2018.3827
30. Preece PE, Mansel RE, Hughes LE. Mastalgia: psychoneurosis or organic disease? Br Med J. 1978;1(6104):29-30. DOI:10.1136/bmj.1.6104.29
31. Johnson KM, Bradley KA, Bush K, et al. Frequency of mastalgia among women veterans. Association with psychiatric conditions and unexplained pain syndromes. J Gen Intern Med. 2006;21Suppl. 3(Suppl. 3):S70-5. DOI:10.1111/j.1525-1497.2006.00378.x
32. Expert Panel on Breast Imaging: Jokich PM, Bailey L, D'Orsi C, et al. ACR Appropriateness Criteria® Breast Pain. J Am Coll Radiol. 2017;14(5S):S25‑33. DOI:10.1016/j.jacr.2017.01.028
33. Leung JW, Kornguth PJ, Gotway MB. Utility of targeted sonography in the evaluation of focal breast pain. J Ultrasound Med. 2002;21(5):521-6. DOI:10.7863/jum.2002.21.5.521
34. Tumyan L, Hoyt AC, Bassett LW. Negative predictive value of sonography and mammography in patients with focal breast pain. Breast J. 2005;11(5):333-7.
DOI:10.1111/j.1075-122X.2005.00018.x
35. Loving VA, DeMartini WB, Eby PR, et al. Targeted ultrasound in women younger than 30 years with focal breast signs or symptoms: outcomes analyses and management implications. AJR Am J Roentgenol. 2010;195(6):1472-7. DOI:10.2214/AJR.10.4396
36. Harper AP, Kelly-Fry E, Noe JS. Ultrasound breast imaging-the method of choice for examining the young patient. Ultrasound Med Biol. 1981;7(3):231-7.
DOI:10.1016/0301-5629(81)90033-8
37. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Heal. 1990;13(4):227-36. DOI:10.1002/nur.4770130405
38. Talimi-Schnabel J, Fink D. Mastodynie – wie soll man «Brustschmerz» abklären und behandeln? Praxis (Bern 1994). 2017;106(20):1101-6 (in German).
DOI:10.1024/1661-8157/a002795
39. Iddon J, Dixon JM. Mastalgia. BMJ. 2013;347:f3288. DOI:10.1136/bmj.f3288
40. Hadi MS. Sports brassiere: is it a solution for mastalgia? Breast J. 2000;6(6):407-9. DOI:10.1046/j.1524-4741.2000.20018.x
41. White J, Scurr J. Evaluation of professional bra fitting criteria for bra selection and fitting in the UK. Ergonomics. 2012;55(6):704-11.
DOI:10.1080/00140139.2011.647096
42. Jaiswal G, Thakur GS. An alternative yogic approach for cyclical mastalgia–A narrative review. J Family Med Prim Care. 2021;10(2):601-8. DOI:10.4103/jfmpc.jfmpc_1688_20
43. Yu C, Wang J, Shen B, et al. Effectiveness of acupuncture in the treatment of cyclic mastalgia: a study protocol for a randomized controlled trial. BMC Complement Med Ther. 2022;22(1):297. DOI:10.1186/s12906-022-03779-8
44. Yu GH, Zou LY, Liu JG. Combination of acupuncture with medication for treatment of hyperplasia of mammary glands in 46 cases. J Tradit Chin Med. 2010;30(3):232-4. DOI:10.1016/s0254-6272(10)60047-7
45. Wang Y. Acupuncture for treatment of hyperplasia of mammary gland and its effects on images and hemodynamics in the mammary gland. Zhongguo Zhen Jiu. 2005;25(9):619-21 (in Chinese).
46. Ernster VL, Goodson WH 3rd, Hunt TK, et al. Vitamin E and benign breast «disease»: double-blind, randomized clinical trial. Surgery. 1985;97(4):490-4.
47. Schürks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomized controlled trials. BMJ. 2010;341:c5702. DOI:10.1136/bmj.c5702
48. Колесникова Л.И., Сутурина Л.В., Гальченко Е.В., и др. Некоторые показатели антиоксидантной системы у женщин с дисгормональной мастопатией в динамике менструального цикла. Журнал акушерства и женских болезней. 2005;54(1):74-7 [Kolesnikova LI, Suturina LV, Gal'chenko EV, et al. Some parameters of antioxidant system in women with dyshormonal mastopathy in dynamics of menstrual cycle. Journal of obstetrics and women's diseases. 2005;54(1):74-7 (in Russian)]. DOI:10.17816/JOWD81580
49. Колесникова Л.И., Осипова Е.В., Гребенкина Л.А., и др. Окислительный стресс при диффузной мастопатии в различные фазы менструального цикла. Журнал акушерства и женских болезней. 2007;56(4):41‑5 [Kolesnikova LI, Osipova EV, Grеbenkina LA, et al. Oxidation stress in women with diffusion mastopathy in dinamics of menstrual cycle. Journal of obstetrics and women's diseases. 2007;56(4):41‑5 (in Russian)].
50. Goyal A, Mansel RE; Efamast Study Group. A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J. 2005;11(1):41-7. DOI:10.1111/j.1075-122X.2005.21492.x
51. Osouli Tabrizi S, Meedya S, Ghassab-Abdollahia N, et al. The effect of the herbal medicine on severity of cyclic mastalgia: a systematic review and meta-analysis. J Complement Integr Med. 2021;19(4):855-68. DOI:10.1515/jcim-2020-0531
52. Colak T, Ipek T, Kanik A, et al. Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment. J Am Coll Surg. 2003;196(4):525-30.
DOI:10.1016/S1072-7515(02)01893-8
53. Coney P, Washenik K, Langley RG, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception. 2001;63(6):297-302. DOI:10.1016/s0010-7824(01)00208-6
54. Uzan S, Denis C, Pomi V, Varin C. Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast disease. Eur J Obstet Gynecol Reprod Biol. 1992;43(3):219-27. DOI:10.1016/0028-2243(92)90177-z
55. Nappi C, Affinito P, Di Carlo C, et al. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease. J Endocrinol Invest. 1992;15(11):801-6. DOI:10.1007/BF03348808
56. Brkic M, Vujovic S, Ivanisevic MF, et al. The influence of progesterone gel therapy in the treatment of fibrocystic breast disease. Open J Obstet Gynecol. 2016;6(5):334-41. DOI:10.4236/ojog.2016.65042
57. Андреева Е.Н., Рожкова Н.И. Эффективность трансдермального геля, содержащего микронизированный прогестерон, в лечении фиброзно-кистозной мастопатии. Результаты российского исследования. Акушерство и гинекология. 2016;12:131-6 [Andreeva EN, Rozhkova NI. Efficacy of micronized progesterone-containing transdermal gel in the treatment of fibrocystic mastopathy: results of a russian study. Akusherstvo i ginekologiia. 2016;12:131-6 (in Russian)]. DOI:10.18565/aig.2016.12.131-6
58. Киселев В.И., Сметник В.П., Сутурина Л.В., и др. Индолкарбинол – метод мультитаргетной терапии при циклической мастодинии. Акушерство и гинекология.
2013;7:56-63 [Kiselev VI, Smetnik VP, Suturina LV, et al. Indole carbinol is a multitargeted therapy option for cyclic mastodynia. Akusherstvo i ginekologiia. 2013;7:56-63 (in Russian)].
59. Mansel RE, Goyal A, Preece P, et al. European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J Obstet Gynecol. 2004;191(6):1942-9. DOI:10.1016/j.ajog.2004.06.100
60. Srivastava A, Mansel RE, Arvind N, et al. Evidence-based management of mastalgia: a meta-analysis of randomized trials. Breast. 2007;16(5):503‑12. DOI:10.1016/j.breast.2007.03.003
61. Zeqiri A, Dermaku-Sopjani M, Sopjani M. The mechanisms underlying the role of Vitex agnus-castus in mastalgia. Bratisl Lek Listy. 2022;123(12):913-8. DOI:10.4149/BLL_2022_147
62. Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus)-pharmacology and clinical indications. Phytomedicine. 2003;10(4):348‑57. DOI:10.1078/094471103322004866
63. Carmichael AR. Can Vitex Agnus Castus be used for the treatment of mastalgia? What is the current evidence? Evid Based Complement Alternat Med. 2008;5(3):247-50. DOI:10.1093/ecam/nem074
64. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322(7279):134-7. DOI:10.1136/bmj.322.7279.134
65. Halaska M, Beles P, Gorkow C, Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast. 1999;8(4):175-81. DOI:10.1054/brst.1999.0039
66. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2003;18(3):191-5. DOI:10.1002/hup.470
67. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med. 2000;9(3):315-20. DOI:10.1089/152460900318515
68. Berger D, Schaffner W, Schrader E, et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet. 2000;264(3):150-3. DOI:10.1007/s004040000123
69. Ooi SL, Watts S, McClean R, Pak SC. Vitex Agnus-Castus for the Treatment of Cyclic Mastalgia: A Systematic Review and Meta-Analysis. J Womens Health (Larchmt). 2020;29(2):262-78. DOI:10.1089/jwh.2019.7770
________________________________________________
2. Grullon S, Bechmann S. Mastodynia. In: StatPearls [Internet], Treasure Island (FL): StatPearls Publishing, 2022; 2023.
3. Stachs A, Stubert J, Reimer T, Hartmann S. Benign Breast Disease in Women. Dtsch Arztebl Int. 2019;116(33-34):565-74. DOI:10.3238/arztebl.2019.0565
4. Kataria K, Dhar A, Srivastava A, et al. A systematic review of current understanding and management of mastalgia. Indian J Surg. 2014;76(3):217-22. DOI:10.1007/s12262-013-0813-8
5. Kulagina NV, Odintsov VA. Mastodiniia: patogenez, diagnostika, lechenie. Akusherstvo i ginekologiia. 2022;6:33-9 (in Russian). DOI:10.18565/aig.2022-6.33-39
6. Kumar S, Rai R, Das V, et al. Visual analogue scale for assessing breast nodularity in non-discrete lumpy breasts: the Lucknow–Cardiff breast nodularity scale. Breast.
2010;19(3):238-42. DOI:10.1016/j.breast.2010.02.002
7. Scurr J, Hedger W, Morris P, Brown N. The prevalence, severity and impact of breast pain in the general population. Breast J. 2014;20(5):508‑13. DOI:10.1111/tbj.12305
8. Sutton GL, O’Malley VP. Treatment of cyclical mastalgia with low dose short term danazol. Br J Clin Pract. 1986;40(2):68-70.
9. Mansel RE, Dogliotti L. European multicenter trial of bromocriptine in cyclical mastalgia. Lancet. 1990;335(8683):190-3. DOI:10.1016/0140-6736(90)90278-d
10. Fentiman IS, Powles TJ. Tamoxifen and benign breast problems. Lancet. 1987;2(8567):1070-2. DOI:10.1016/s0140-6736(87)91491-7
11. Ader DN, South-Paul J, Adera T, Deuster PA. Cyclical mastalgia: prevalence and associated health behavioral factors. J Psychosom Obstet Gynaecol. 2001;22(2):71-6. DOI:10.3109/01674820109049956
12. Mansel RE, Webster DJT, Sweetland HM. Breast pain and nodularity. In: Benign disorders and disease of the breast. 3d ed. Philadelphia: Saunders, Elsevier, 2009.
13. Padden DL. Mastalgia: evaluation and management. Nurse Pract Forum. 2000;11(4):213-8.
14. Rungruang B, Kelley JL 3rd. Benign breast diseases: epidemiology, evaluation, and management. Clin Obstet Gynecol. 2011;54(1):110-24. DOI:10.1097/GRF.0b013e318208010e
15. Wisbey JR, Kumar S, Mansel RE, et al. Natural history of breast pain. Lancet. 1983;2(8351):672-4. DOI:10.1016/S0140-6736(83)92543-6
16. Goyal A. Breast pain. BMJ Clin Evid. 2011;2011:0812.
17. Malarkey WB, Schrooeder LL, Stevens VC, et al. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res.
1977;37(12):4655-9.
18. Sitruk-Ware R, Sterkers N, Mauvais-Jarvis P. Benign breast disease I: hormonal investigation. Obstet Gynecol. 1979;53(4):457-60.
19. Peters F, Pickcardt CR, Zimmermann G, Breckwoldt M. PRL, TSH and thyroid hormones in benign breast diseases. Klin Wochenschr. 1981;59(8):403-7. DOI:10.1007/BF01698519
20. Kumar S, Mansel RE, Scanlon MF, et al. Altered responses of prolactin, luteinizing hormone and follicle stimulating hormone secretion to thyrotrophin releasing hormone/gonadotropin releasing hormone stimulation in cyclical mastalgia. Br J Surg. 1984;71(11):870-3. DOI:10.1002/bjs.1800711123
21. Parlati E, Travaglini A, Liberale I, et al. Hormonal profile in benign breast disease: Endocrine status of cyclical mastalgia patients. J Endocrinol Invest. 1988;11(9):679-83. DOI:10.1007/BF03350214
22. Bonilla-Sepulveda OA, Giraldo-Santa DC. Mastodynia. CES Med. 2019;33(2):111-8. DOI:10.21615/cesmedicina.33.2.4
23. Ledina AV, Prilepskaya VN. Mastalgiya: klinika, diagnostika, lechenie. Gynecology. 2011;13(5):66-76 (in Russian).
24. Leshchenko OYa. Hyperprolactinemia in the postmenopause: versions and contraversions. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(10):1234‑9 (in Russian). DOI:10.26442/00403660.2021.10.201073
25. Bundred NJ. Breast pain. BMJ Clin Evid. 2007;2007:0812.
26. Labygina AV, Suturina LV, Leshenko OYa. Change of prolactin against a background of intake of oral contraceptives in girls with functional hyperprolactinemia. Biulleten' VSNTs SO RAMN. 2006;1(47):79-81 (in Russian).
27. Boyle CA, Berkowitz GS, LiVolsi VA, et al. Caffeine consumption and fibrocystic breast disease: a case-control epidemiologic study. J Natl Cancer Inst. 1984;72(5):1015-9.
28. Levinson W, Dunn PM. Nonassociation of caffeine and fibrocystic breast disease. Arch Intern Med. 1986;146(9):1773-5.
29. Idiz C, Çakır C, Ulusoy Aİ, İdiz UO. The Role of Nutrition in Women with Benign Cyclic Mastalgia: A Case-Control Study. Eur J Breast Health. 2018;14(3):156-9. DOI:10.5152/ejbh.2018.3827
30. Preece PE, Mansel RE, Hughes LE. Mastalgia: psychoneurosis or organic disease? Br Med J. 1978;1(6104):29-30. DOI:10.1136/bmj.1.6104.29
31. Johnson KM, Bradley KA, Bush K, et al. Frequency of mastalgia among women veterans. Association with psychiatric conditions and unexplained pain syndromes. J Gen Intern Med. 2006;21Suppl. 3(Suppl. 3):S70-5. DOI:10.1111/j.1525-1497.2006.00378.x
32. Expert Panel on Breast Imaging: Jokich PM, Bailey L, D'Orsi C, et al. ACR Appropriateness Criteria® Breast Pain. J Am Coll Radiol. 2017;14(5S):S25‑33. DOI:10.1016/j.jacr.2017.01.028
33. Leung JW, Kornguth PJ, Gotway MB. Utility of targeted sonography in the evaluation of focal breast pain. J Ultrasound Med. 2002;21(5):521-6. DOI:10.7863/jum.2002.21.5.521
34. Tumyan L, Hoyt AC, Bassett LW. Negative predictive value of sonography and mammography in patients with focal breast pain. Breast J. 2005;11(5):333-7.
DOI:10.1111/j.1075-122X.2005.00018.x
35. Loving VA, DeMartini WB, Eby PR, et al. Targeted ultrasound in women younger than 30 years with focal breast signs or symptoms: outcomes analyses and management implications. AJR Am J Roentgenol. 2010;195(6):1472-7. DOI:10.2214/AJR.10.4396
36. Harper AP, Kelly-Fry E, Noe JS. Ultrasound breast imaging-the method of choice for examining the young patient. Ultrasound Med Biol. 1981;7(3):231-7.
DOI:10.1016/0301-5629(81)90033-8
37. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Heal. 1990;13(4):227-36. DOI:10.1002/nur.4770130405
38. Talimi-Schnabel J, Fink D. Mastodynie – wie soll man «Brustschmerz» abklären und behandeln? Praxis (Bern 1994). 2017;106(20):1101-6 (in German).
DOI:10.1024/1661-8157/a002795
39. Iddon J, Dixon JM. Mastalgia. BMJ. 2013;347:f3288. DOI:10.1136/bmj.f3288
40. Hadi MS. Sports brassiere: is it a solution for mastalgia? Breast J. 2000;6(6):407-9. DOI:10.1046/j.1524-4741.2000.20018.x
41. White J, Scurr J. Evaluation of professional bra fitting criteria for bra selection and fitting in the UK. Ergonomics. 2012;55(6):704-11.
DOI:10.1080/00140139.2011.647096
42. Jaiswal G, Thakur GS. An alternative yogic approach for cyclical mastalgia–A narrative review. J Family Med Prim Care. 2021;10(2):601-8. DOI:10.4103/jfmpc.jfmpc_1688_20
43. Yu C, Wang J, Shen B, et al. Effectiveness of acupuncture in the treatment of cyclic mastalgia: a study protocol for a randomized controlled trial. BMC Complement Med Ther. 2022;22(1):297. DOI:10.1186/s12906-022-03779-8
44. Yu GH, Zou LY, Liu JG. Combination of acupuncture with medication for treatment of hyperplasia of mammary glands in 46 cases. J Tradit Chin Med. 2010;30(3):232-4. DOI:10.1016/s0254-6272(10)60047-7
45. Wang Y. Acupuncture for treatment of hyperplasia of mammary gland and its effects on images and hemodynamics in the mammary gland. Zhongguo Zhen Jiu. 2005;25(9):619-21 (in Chinese).
46. Ernster VL, Goodson WH 3rd, Hunt TK, et al. Vitamin E and benign breast «disease»: double-blind, randomized clinical trial. Surgery. 1985;97(4):490-4.
47. Schürks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomized controlled trials. BMJ. 2010;341:c5702. DOI:10.1136/bmj.c5702
48. Kolesnikova LI, Suturina LV, Gal'chenko EV, et al. Some parameters of antioxidant system in women with dyshormonal mastopathy in dynamics of menstrual cycle. Journal of obstetrics and women's diseases. 2005;54(1):74-7 (in Russian). DOI:10.17816/JOWD81580
49. Kolesnikova LI, Osipova EV, Grеbenkina LA, et al. Oxidation stress in women with diffusion mastopathy in dinamics of menstrual cycle. Journal of obstetrics and women's diseases. 2007;56(4):41‑5 (in Russian).
50. Goyal A, Mansel RE; Efamast Study Group. A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J. 2005;11(1):41-7. DOI:10.1111/j.1075-122X.2005.21492.x
51. Osouli Tabrizi S, Meedya S, Ghassab-Abdollahia N, et al. The effect of the herbal medicine on severity of cyclic mastalgia: a systematic review and meta-analysis. J Complement Integr Med. 2021;19(4):855-68. DOI:10.1515/jcim-2020-0531
52. Colak T, Ipek T, Kanik A, et al. Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment. J Am Coll Surg. 2003;196(4):525-30.
DOI:10.1016/S1072-7515(02)01893-8
53. Coney P, Washenik K, Langley RG, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception. 2001;63(6):297-302. DOI:10.1016/s0010-7824(01)00208-6
54. Uzan S, Denis C, Pomi V, Varin C. Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast disease. Eur J Obstet Gynecol Reprod Biol. 1992;43(3):219-27. DOI:10.1016/0028-2243(92)90177-z
55. Nappi C, Affinito P, Di Carlo C, et al. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease. J Endocrinol Invest. 1992;15(11):801-6. DOI:10.1007/BF03348808
56. Brkic M, Vujovic S, Ivanisevic MF, et al. The influence of progesterone gel therapy in the treatment of fibrocystic breast disease. Open J Obstet Gynecol. 2016;6(5):334-41. DOI:10.4236/ojog.2016.65042
57. Andreeva EN, Rozhkova NI. Efficacy of micronized progesterone-containing transdermal gel in the treatment of fibrocystic mastopathy: results of a russian study. Akusherstvo i ginekologiia. 2016;12:131-6 (in Russian). DOI:10.18565/aig.2016.12.131-6
58. Kiselev VI, Smetnik VP, Suturina LV, et al. Indole carbinol is a multitargeted therapy option for cyclic mastodynia. Akusherstvo i ginekologiia. 2013;7:56-63 (in Russian).
59. Mansel RE, Goyal A, Preece P, et al. European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J Obstet Gynecol. 2004;191(6):1942-9. DOI:10.1016/j.ajog.2004.06.100
60. Srivastava A, Mansel RE, Arvind N, et al. Evidence-based management of mastalgia: a meta-analysis of randomized trials. Breast. 2007;16(5):503‑12. DOI:10.1016/j.breast.2007.03.003
61. Zeqiri A, Dermaku-Sopjani M, Sopjani M. The mechanisms underlying the role of Vitex agnus-castus in mastalgia. Bratisl Lek Listy. 2022;123(12):913-8. DOI:10.4149/BLL_2022_147
62. Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus)-pharmacology and clinical indications. Phytomedicine. 2003;10(4):348‑57. DOI:10.1078/094471103322004866
63. Carmichael AR. Can Vitex Agnus Castus be used for the treatment of mastalgia? What is the current evidence? Evid Based Complement Alternat Med. 2008;5(3):247-50. DOI:10.1093/ecam/nem074
64. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322(7279):134-7. DOI:10.1136/bmj.322.7279.134
65. Halaska M, Beles P, Gorkow C, Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast. 1999;8(4):175-81. DOI:10.1054/brst.1999.0039
66. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2003;18(3):191-5. DOI:10.1002/hup.470
67. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med. 2000;9(3):315-20. DOI:10.1089/152460900318515
68. Berger D, Schaffner W, Schrader E, et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet. 2000;264(3):150-3. DOI:10.1007/s004040000123
69. Ooi SL, Watts S, McClean R, Pak SC. Vitex Agnus-Castus for the Treatment of Cyclic Mastalgia: A Systematic Review and Meta-Analysis. J Womens Health (Larchmt). 2020;29(2):262-78. DOI:10.1089/jwh.2019.7770
Авторы
О.Я. Лещенко*
ФГБНУ «Научный центр проблем здоровья семьи и репродукции человека», Иркутск, Россия
*loyairk@mail.ru
Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russia
*loyairk@mail.ru
ФГБНУ «Научный центр проблем здоровья семьи и репродукции человека», Иркутск, Россия
*loyairk@mail.ru
________________________________________________
Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russia
*loyairk@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.